Japan updates its official notices for several cancer drugs
Original title: PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; tovorafenib and dordaviprone for glioma, mirvetuximab soravtansine and pembrolizumab for ovarian cancer, tislelizumab for nasopharyngeal cancer, trastuzumab deruxtecan, palbociclib and datopotamab deruxtecan for breast cancer, epcoritamab for lymphoma, teclistamab for multiple myeloma.
How far along is this research?
This is a news item, not a research finding.
These drugs have gone through Japan's approval process, so doctors there can use them.
The short version
Japan's drug agency has approved some cancer drugs and changed the safety notes for others.
What was studied. This is a notice from PMDA, the drug agency in Japan. It lists cancer drugs that were approved, plus drugs whose safety warnings were updated.
What they found. Two of the drugs on the list are for glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary, a kind of brain tumor. They are tovorafenib and dordaviprone. The list also names drugs for ovarian, breast, and other cancers. No study details or results came with this notice.
What this means, and what it doesn't
What it could mean: Two glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary drugs now appear in Japan's official drug notices. That means regulators there have acted on them. Rules in other countries can be different. Your doctor can tell you what is available where you live.
What it doesn't mean: This is not a new study, and it is not a cure. It is a regulatory notice, not a test of how well these drugs work. It does not say either drug will help you. It also does not mean they are approved in your country. On its own, this changes nothing about your care.
Source: PubMed, October 3, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.